Alto Neuroscience, Inc. ANRO
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 9.10% | -5.34% | -62.14% | -14.11% | 19.91% |
| Total Depreciation and Amortization | -1.63% | 0.00% | 17.20% | -4.27% | -2.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.95% | 20.77% | 39.27% | -14.03% | 13.76% |
| Change in Net Operating Assets | -105.13% | 182.90% | -309.19% | 61.91% | 0.15% |
| Cash from Operations | -5.04% | 27.06% | -135.25% | -16.11% | 28.02% |
| Capital Expenditure | -- | 100.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 129,121.33% | -99.94% | 138.33% | 32,809.80% | -- |
| Repurchase of Common Stock | -- | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -58.33% | 92.86% | -2,819.16% | -- | 100.00% |
| Cash from Financing | 35,398.53% | -100.24% | 129.03% | 32,700.65% | -75.04% |
| Foreign Exchange rate Adjustments | -50.00% | 125.00% | -1,500.00% | 75.00% | -33.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 477.51% | -122.95% | 125.71% | 495.82% | 25.82% |